Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Variant on the Efficacy of Alectinib in Untreated ALK-Positive Advanced Non–Small Cell Lung Cancer in the Global Phase III ALEX Study

D. Ross Camidge; Rafał Dziadziuszko; Solange Peters; Tony Mok; Johannes Noé; Małgorzata Nowicka; Shirish M. Gadgeel; Parneet Cheema; Nick Pavlakis; Filippo de Marinis; Byoung Chul Cho; Li Zhang; Denis Moro‐Sibilot; Ting Liu; Walter Bordogna; Bogdana Balas; Bárbara Müller; Alice T. Shaw

doi:10.1016/j.jtho.2019.03.007

Abstract

This is the authors' abstract. We don't add key points for this paper.

Alectinib continues to demonstrate superior investigator-assessed PFS versus crizotinib in untreated ALK-positive NSCLC, irrespective of EML4-ALK variant.

Ask about this paper

Answers are grounded in this paper and cite their sources.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Camidge et al. (2019) studied this question.

synapsesocial.com/papers/69d7c6f005ee2ba81dbede09 https://doi.org/10.1016/j.jtho.2019.03.007

View Full Paper

Ask AI

Bookmark

Share

Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Variant on the Efficacy of Alectinib in Untreated ALK-Positive Advanced Non–Small Cell Lung Cancer in the Global Phase III ALEX Study

Abstract

Ask about this paper

Discussion

Cite This Study

Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Variant on the Efficacy of Alectinib in Untreated ALK-Positive Advanced Non–Small Cell Lung Cancer in the Global Phase III ALEX Study

Abstract

Ask about this paper

Discussion

Cite This Study

Keep reading

Keep reading